Introduction
============

Ampullary carcinomas are malignancies arising in the vicinity of the ampulla of Vater, a confluence of the distal common bile duct and the main pancreatic duct into the duodenum. Primary tumors of the ampulla of Vater are rather rare with an incidence of nearly five per million population and account for just 6% of periampullary cancer.[@b1-cmar-11-217],[@b2-cmar-11-217] Complete surgical resection is the only curative way of treating ampullary carcinomas.[@b3-cmar-11-217],[@b4-cmar-11-217] Due to the earlier presentation of biliary obstruction and other symptoms, there are higher resectability rates and higher 5-year survival rates in ampullary cancer than in other periampullary cancers, namely, pancreatic head cancer and distal cholangiocarcinoma.[@b5-cmar-11-217],[@b6-cmar-11-217]

However, there are always a small minority of patients with metastasis at initial diagnosis who experience a poor prognosis with a 5-year survival rate close to 0%.[@b7-cmar-11-217] Because of the rarity of this disease, the optimal management for systemic therapy such as standard chemotherapy regimen has not been well established for these advanced cancer patients.[@b8-cmar-11-217],[@b9-cmar-11-217] In view of the disappointing efficacy of current approaches, other therapeutic methods need to be explored in the future.

A large body of researches have reported the favorable role of primary tumor resection (PTR) in some advanced cancers such as breast cancer,[@b10-cmar-11-217] bladder cancer,[@b11-cmar-11-217] head and neck squamous cell cancer and colorectal cancer.[@b12-cmar-11-217]--[@b14-cmar-11-217] Palliative bypass surgery was carried out in some advanced periampullary cancer patients for the purpose of relieving symptoms and resulted in improved quality of life.[@b15-cmar-11-217] However, there is still no population-based study to explore the survival prolongation after PTR, particularly in advanced ampullary cancer.

Hence, we used population-based data from Surveillance, Epidemiology and End Results (SEER) database to assess the therapeutic value of PTR in metastatic ampullary cancer at the initial presentation and explore the combined power of PTR plus chemotherapy.

Patients and methods
====================

Study population
----------------

Eligible patients were screened from the SEER database. The inclusion criteria are listed as follows: 1) ampullary cancer as the first primary cancer; 2) the cancer diagnosed between 2004 and 2014 because detailed information on tumor size was not available before 2004 and the cutoff follow-up date of the latest released SEER data was December 31, 2014; 3) ampullary cancer patients with distant metastasis at the initial presentation; 4) age at diagnosis older than 18 and younger than 80 (97 patients were excluded, including 3 patients receiving PTR); 5) definite information on whether patients received PTR (6 patients were excluded, as 5 of them did not record what surgery they did and 1 patient did not record whether the surgery was done); 6) survival time was at least 1 month to reduce selection bias (23 patients were excluded and none of them received PTR); 7) patients without death certificate were excluded (5 patients were excluded and none of them received PTR); these are presented in [Figure 1](#f1-cmar-11-217){ref-type="fig"}. The data accessed from the SEER database are freely available. This study was approved by the Research Medical Ethics Committee Institutional Review Boards of Fudan University Zhongshan Hospital.

Covariates and outcomes
-----------------------

Baseline characteristics including age, sex and race, tumor grade, tumor size, T stage, N stage, PTR, radiotherapy and chemotherapy were collected. PTR referred to partial or total surgical removal of the primary tumor with or without an en bloc resection of other organs, but not local tumor destructive methods such as laser excision and excisional biopsy. Radiotherapy referred to external beam radiation therapy, radioactive implants and radioisotopes. Histologic type was not incorporated in the analyses because \>90% of those patients represent adenocarcinoma. Histologic subtypes such as "pan-creaticobiliary subtypes" and "intestinal subtypes" were also not incorporated in the analyses due to the lack of available data within the SEER database. Patients with unknown tumor size or grade were recorded as "Unspecified". The primary endpoints of the study were overall survival (OS) and cancer-specific survival (CSS). Survival time was calculated from the date of diagnosis to the date of death or the last follow-up.

Statistical analysis
--------------------

Continuous variables were compared by Student's *t*-test and categorical variables by Pearson's chi-squared test or Fisher's exact test, as indicated. A one-to-one propensity score matching (PSM) with a caliper of 0.005 was performed to ensure that the characteristics of the PSM cohort were balanced. Kaplan--Meier methods and log-rank tests were used to assess the significant differences in OS and CSS. Multivariate Cox proportional hazards regression analysis was employed to evaluate the prognostic factors, and HRs along with 95% CI were calculated. Student's *t*-test, Pearson's chi-squared test, Fisher's exact test, PSM and multivariate Cox regression analyses were performed by IBM SPSS version 22 (IBM Corporation, Armonk, NY, USA). Kaplan--Meier survival curves and log-rank tests were conducted by GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA, USA). Forest plots summarizing HRs for PTR vs no-PTR in the subgroup multivariate analyses were performed by R program version 3.4.0 (<http://www.r-project.org>). A two-sided *P*-value \<0.05 indicated statistical significance.

Results
=======

Study cohort selection and baseline characteristics
---------------------------------------------------

In total, 346 patients with metastatic ampullary cancer at the initial presentation were enrolled in our study. Among the 346 patients, PTR was carried out in less than one-fifth of the overall patients (n=63, 18.2%). The mean age at diagnosis was 63.4 years. Almost two-thirds (n=231, 66.8%) of the patients received chemotherapy, while only one-ninth (n=38, 11.0%) of the patients received radiotherapy. Baseline characteristics across PTR and no-PTR groups are shown in [Table 1](#t1-cmar-11-217){ref-type="table"}. Significant differences (*P*\<0.05) were observed in the race, tumor size, grade, T stage and N stage. To balance the characteristics of the two cohorts and reduce the selection bias as much as possible, PSM was performed on the basis of the above factors (race, tumor size, grade, T stage and N stage). As shown in [Table 2](#t2-cmar-11-217){ref-type="table"}, a total of 90 patients were included finally, and all the characteristics of the PSM cohort were balanced.

### Therapeutic value of PTR in the overall cohort

The effect of PTR on OS and CSS was evaluated in the overall cohort and the PSM cohort. As shown in [Figure 2](#f2-cmar-11-217){ref-type="fig"}, the survival analysis by log-rank test showed PTR was significantly associated with improved survival for the overall cohort (PTR vs no-PTR: 18.0, 95% CI: 13.0--23.0 vs 7.0, 95% CI: 6.0--8.0 for median OS; 21.0, 95% CI: 14.0--27.0 vs 7.0, 95% CI: 6.0--8.0 for median CSS; both log-rank *P*\<0.001) and the PSM cohort (PTR vs no-PTR: 16.0, 95% CI: 9.0--22.0 vs 8.0, 95% CI: 5.0--11.0 for median OS; 22.0, 95% CI: 13.0--33.0 vs 9.0, 95% CI: 5.0--11.0 for median CSS; both log-rank *P*\<0.001). Baseline characteristics of the overall cohort and the PSM cohort are presented in [Tables S1](#SD4-cmar-11-217){ref-type="supplementary-material"} and [S2](#SD5-cmar-11-217){ref-type="supplementary-material"}. After adjusting for other covariates, PTR still acted as a favorable predictor for both OS and CSS (PTR vs no-PTR, HR: 0.365, 95% CI: 0.251--0.531, *P*\<0.001 for OS; HR: 0.331, 95% CI: 0.223--0.492, *P*\<0.001 for CSS), as shown in [Table 3](#t3-cmar-11-217){ref-type="table"}.

### Therapeutic value of combination of PTR and chemotherapy

As chemotherapy is the most commonly used method for advanced ampullary cancer patients for the time being, we evaluated its therapeutic effect in the meantime. As shown in [Figure S1](#SD1-cmar-11-217){ref-type="supplementary-material"} and [Figure 3A](#f3-cmar-11-217){ref-type="fig"}, patients receiving chemotherapy showed a survival benefit compared with patients not receiving chemotherapy, no matter before PSM (chemotherapy vs no chemotherapy: 10.0, 95% CI: 8.0--13.0 vs 4.0, 95% CI: 3.0--5.0 for median OS; 10.0, 95% CI: 8.0--14.0 vs 4.0, 95% CI: 3.0--5.0 for median CSS; both log-rank *P*\<0.001) or after PSM (chemotherapy vs no chemotherapy: 10.0, 95% CI: 8.0--13.0 vs 4.0, 95% CI: 3.0--5.0 for median OS; 10.0, 95% CI: 8.0--14.0 vs 4.0, 95% CI: 3.0--5.0 for median CSS; both log-rank *P*\<0.001). The baseline characteristics of the whole cohort and the PSM cohort are shown in [Tables S1](#SD4-cmar-11-217){ref-type="supplementary-material"} and [S2](#SD5-cmar-11-217){ref-type="supplementary-material"}. Simultaneously, chemotherapy is still an independent favorable prognostic factor after the multivariate analysis, in accordance with previous clinical trials ([Table 3](#t3-cmar-11-217){ref-type="table"}).[@b9-cmar-11-217]

Furthermore, it was found that the therapeutic effect of PTR still existed regardless of receiving chemotherapy or not on multivariate analyses within chemotherapy subgroups (PTR vs no-PTR in "chemotherapy" group, HR: 0.447, 95% CI: 0.282--0.709 for OS; HR: 0.397, 95% CI: 0.243--0.649 for CSS; PTR vs no-PTR in "no chemotherapy" group, HR: 0.259, 95% CI: 0.129--0.521 for OS; HR: 0.233, 95% CI: 0.113--0.481 for CSS), as shown in [Figure S2](#SD2-cmar-11-217){ref-type="supplementary-material"}. In order to achieve the best therapeutic effect, we then considered whether patients could benefit more from the combination of PTR and chemotherapy or not. In the Kaplan--Meier curves, patients who received both PTR and chemotherapy showed a better survival advantage compared to patients only receiving chemotherapy (median OS: 18, 95% CI: 13--27 vs 9.0, 95% CI: 8.0--11.0; median CSS: 23.0, 95% CI: 14.0--36.0 vs 9.0, 95% CI: 8.0--13.0; log-rank *P*\<0.001), as shown in [Figure 3B](#f3-cmar-11-217){ref-type="fig"}. Furthermore, we also noticed the high percentage of patients alive at 5 years in the group treated by surgery and chemotherapy compared with patients only receiving chemotherapy (11.9% vs 1.1%, *P*\<0.001).

Therapeutic value of PTR in other subgroups
-------------------------------------------

Subsequently, subgroup analyses were separately performed according to T stage and age at diagnosis, as they are the most easily available clinical information for advanced ampullary cancer patients. As shown in [Figures S2](#SD2-cmar-11-217){ref-type="supplementary-material"} and [S3](#SD3-cmar-11-217){ref-type="supplementary-material"}, PTR still independently predicted favorable OS and CSS in all the T stage subgroups and age subgroups.

Discussion
==========

In this study, we explored the therapeutic roles of PTR for metastatic ampullary cancer patients at the initial presentation using a large cohort of metastatic ampullary cancer patients. Most importantly, our study evaluated the prognostic efficacy of combination of PTR plus chemotherapy, which proved to be a more efficient strategy. The above findings differed from our original concept of management for metastatic ampullary cancer patients, but they might indeed provide us a new treatment option and could serve as the theoretical basis of further prospective studies.

Obstructive jaundice (80%) caused by the compression of distal bile duct by the tumor is the most common presenting symptom of ampullary cancer.[@b16-cmar-11-217],[@b17-cmar-11-217] PTR could alleviate pruritus, anorexia, fat malabsorption, vitamin K deficiency and diarrhea through relieving obstructive jaundice to avoid coagulopathy, cholangitis, liver failure and cachexia.[@b18-cmar-11-217] Up to 38% of patients die from biliary obstruction if no prophylactic treatment is administered.[@b19-cmar-11-217] At the same time, alleviation of tumor load could reduce the risk of anemia, hypoproteinemia and cachexia too.[@b20-cmar-11-217] On the other hand, primary tumor might be the source of seed and promote the development of new and existing metastases, whereby its removal might theoretically delay the tumor progression.[@b21-cmar-11-217],[@b22-cmar-11-217] However, there is not any consensus on the mechanism underlying the surgery-derived benefits, and the hypothesis given above needs to be validated in ampullary cancer.

As the dominant treatment for patients with metastasis, chemotherapy strategies such as the combination of gemcitabine and cisplatin represent significant survival benefits in some clinical trials, but a consensus about the therapeutic efficacy of these regimens has not been reached yet.[@b9-cmar-11-217] Moreover, many of these clinical trials are combined series that include patients with pancreatic, biliary tract and ampullary cancer.[@b8-cmar-11-217] In our study, we indeed noticed that patients receiving chemotherapy could experience a significant but modest survival advantage compared to others not receiving chemotherapy, although we could not further analyze the impact of chemotherapy as the details about chemotherapy regimens are not available. More interestingly, its conjunction with PTR could greatly improve the prognosis of patients. That is, the conjunction might provide both short- and long-term survival benefits. Hence, the more aggressive strategy of PTR plus chemotherapy might be taken into consideration for patients who could tolerate it. As we know, optimal management for systemic therapy has not well been established for these advanced cancer patients. Our finding might add a reasonable method and extend the treatment spectrum for them.

In spite of the intriguing results, some inevitable limitations must be shown clearly. The major limitation came from the SEER dataset itself. For instance, there was a lack of details concerning the surgical procedure, location and size of metastases, chemotherapy regimen and the clinical status of patients at initial diagnosis. Histologic subtype is an important prognostic factor in ampullary cancer, but there is still no detailed record in the SEER database. So, even though PSM was used, some bias might still exist. Finally, due to the retrospective nature of our study, prospective research needs to be conducted in the future.

In conclusion, this population-based study proved the potentially favorable influence of PTR on survival in advanced ampullary cancer patients at the initial presentation, and combined utilization of PTR plus chemotherapy might provide more favorable survival.

Supplementary materials
=======================

###### 

Kaplan--Meier curves of overall (**A**) and cancer-specific survival (**B**) according to whether chemotherapy was received or not in the overall cohort before PSM (n=346).

**Abbreviation:** PSM, propensity score matching.

###### 

Forest plots summarizing the HRs and 95% CIs of overall survival (**A**) and CSS (**B**) for PTR vs no-PTR in subgroup analyses.

**Abbreviations:** CSS, cancer-specific survival; PSM, propensity score matching; PTR, primary tumor resection.

###### 

Kaplan--Meier curves of overall and cancer-specific survival according to whether or not PTR was performed in the T1--2 subgroup (**A**), T3--4 subgroup (**B**), age \<65 subgroup (**C**) and age ≥65 subgroup (**D**).

**Abbreviation:** PTR, primary tumor resection.

###### 

Baseline characteristics of metastatic ampullary cancer patients before PSM

  Characteristics        Total         Chemotherapy   No chemotherapy   *P*-value
  ---------------------- ------------- -------------- ----------------- -------------
                                                                        
  **Age at diagnosis**                                                  **\<0.001**
  Mean ± SD              63.4±10.7     61.8±10.9      66.7±9.4          
  **Sex**                                                               0.667
  Female                 144 (41.6%)   98 (42.4%)     46 (40.0%)        
  Male                   202 (58.4%)   133 (57.6%)    69 (60.0%)        
  **Race**                                                              0.604
  White                  261 (75.4%)   178 (77.1%)    83 (72.2%)        
  Black                  47 (13.6%)    29 (12.6%)     18 (15.6%)        
  Other                  38 (11.0%)    24 (10.3%)     14 (12.2%)        
  **Tumor size, cm**                                                    0.149
  \<3                    89 (25.7%)    63 (27.3%)     26 (22.6%)        
  ≥3                     102 (29.5%)   73 (31.6%)     29 (25.2%)        
  Unspecified            155 (44.8%)   95 (41.1%)     60 (52.2%)        
  **Grade**                                                             0.962
  High                   27 (7.8%)     18 (7.8%)      9 (7.8%)          
  Moderate               102 (29.5%)   66 (28.6%)     36 (31.3%)        
  Low                    96 (27.7%)    65 (28.1%)     31 (27.0%)        
  Unspecified            121 (35.0%)   82 (35.5%)     39 (33.9%)        
  **T stage**                                                           0.055
  T1--2                  120 (34.7%)   78 (33.8%)     42 (36.5%)        
  T3                     56 (16.2%)    41 (17.8%)     15 (13.0%)        
  T4                     96 (27.7%)    63 (27.2%)     33 (28.7%)        
  Tx                     74 (21.4%)    49 (21.2%)     25 (21.8%)        
  **N stage**                                                           0.755
  N0                     152 (43.9%)   99 (42.9%)     53 (46.1%)        
  N+                     136 (39.3%)   94 (40.7%)     42 (36.5%)        
  Nx                     58 (16.8%)    38 (16.4%)     20 (17.4%)        
  **Radiation**                                                         0.061
  No evidence            308 (89.0%)   200 (86.6%)    108 (93.9%)       
  Yes                    38 (11.0%)    31 (13.4%)     7 (6.1%)          
  **Surgery**                                                           0.986
  No surgery             283 (81.8%)   189 (81.8%)    94 (81.7%)        
  Surgery                63 (18.2%)    42 (18.2%)     21 (18.3%)        

**Notes:** *P*\<0.05 is considered statistically significant. Statistically significant value is shown in bold.

**Abbreviation:** PSM, propensity score matching.

###### 

Baseline characteristics of metastatic ampullary cancer patients after PSM

  Characteristics        Total         Chemotherapy   No chemotherapy   *P-*value
  ---------------------- ------------- -------------- ----------------- -----------
                                                                        
  **Age at diagnosis**                                                  0.670
  Mean ± SD              66.2±9.2      65.7±9.0       66.7±9.3          
  **Sex**                                                               0.232
  Female                 102 (44.4%)   46 (40.0%)     56 (48.7%)        
  Male                   128 (55.6%)   69 (60.0%)     59 (51.3%)        
  **Race**                                                              0.380
  White                  175 (76.1%)   83 (72.2%)     92 (80.0%)        
  Black                  31 (13.5%)    18 (15.6%)     13 (11.3%)        
  Other                  24 (10.4%)    14 (12.2%)     10 (8.7%)         
  **Tumor size, cm**                                                    0.409
  \<3                    58 (25.2%)    26 (22.6%)     32 (27.8%)        
  ≥3                     62 (27.0%)    29 (25.2%)     33 (28.7%)        
  Unspecified            110 (47.8%)   60 (52.2%)     50 (43.5%)        
  **Grade**                                                             0.655
  High                   16 (7.0%)     9 (7.8%)       7 (6.1%)          
  Moderate               67 (29.1%)    36 (31.3%)     31 (27.0%)        
  Low                    60 (26.1%)    31 (27.0%)     29 (25.2%)        
  Unspecified            87 (37.8%)    39 (33.9%)     48 (41.7%)        
  **T stage**                                                           0.269
  T1--2                  86 (37.4%)    42 (36.5%)     44 (38.3%)        
  T3                     28 (12.2%)    15 (13.1%)     13 (11.3%)        
  T4                     66 (28.7%)    33 (28.7%)     33 (28.7%)        
  Tx                     50 (21.7%)    25 (21.7%)     25 (21.7%)        
  **N stage**                                                           0.800
  N0                     101 (43.9%)   53 (46.1%)     48 (41.7%)        
  N+                     87 (37.8%)    42 (36.5%)     45 (39.1%)        
  Nx                     42 (18.2%)    20 (17.4%)     22 (19.2%)        
  **Radiation**                                                         0.079
  No evidence            207 (90.0%)   108 (93.9%)    99 (86.1%)        
  Yes                    23 (10.0%)    7 (6.1%)       16 (13.9%)        
  **Surgery**                                                           0.364
  No surgery             194 (84.3%)   94 (81.7%)     100 (87.0%)       
  Surgery                36 (15.7%)    21 (18.3%)     15 (13.0%)        

**Notes:** PSM was performed according to age and T stage with a caliper of 0.005. *P*\<0.05 is considered statistically significant.

**Abbreviation:** PSM, propensity score matching.
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![Flowchart of inclusion and exclusion in the study.\
**Abbreviation:** PTR, primary tumor resection.](cmar-11-217Fig1){#f1-cmar-11-217}

![Kaplan--Meier curves of overall and cancer-specific survival according to whether PTR was performed or not in the overall cohort before PSM (n=346) (**A**) and the PSM cohort after PSM (n=90) (**B**).\
**Abbreviations:** PSM, propensity score matching; PTR, primary tumor resection.](cmar-11-217Fig2){#f2-cmar-11-217}

![Kaplan--Meier curves of overall and cancer-specific survival according to whether chemotherapy was received or not in the PSM cohort (n=230) (**A**) and the status of combination of PTR and chemotherapy in the overall cohort (n=346) (**B**).\
**Abbreviations:** PSM, propensity score matching; PTR, primary tumor resection.](cmar-11-217Fig3){#f3-cmar-11-217}

###### 

Baseline characteristics of metastatic ampullary cancer patients before PSM

  Characteristics        Total         PTR          No-PTR        *P*-value
  ---------------------- ------------- ------------ ------------- -------------
                                                                  
  **Age at diagnosis**                                            0.179
  Mean ± SD              63.4±10.7     61.8±10.8    63.8±10.6     
  **Sex**                                                         0.442
  Female                 144 (41.6%)   23 (36.5%)   121 (42.8%)   
  Male                   202 (58.4%)   40 (63.5%)   162 (57.2%)   
  **Race**                                                        **0.009**
  White                  261 (75.4%)   38 (60.3%)   223 (78.8%)   
  Black                  47 (13.6%)    14 (22.2%)   33 (11.7%)    
  Other                  38 (11.0%)    11 (17.5%)   27 (9.5%)     
  **Tumor size, cm**                                              **\<0.001**
  \<3                    89 (25.7%)    28 (44.4%)   61 (21.6%)    
  ≥3                     102 (29.5%)   27 (42.9%)   75 (26.5%)    
  Unspecified            155 (44.8%)   8 (12.7%)    147 (51.9%)   
  **Grade**                                                       **\<0.001**
  High                   27 (7.8%)     6 (9.5%)     21 (7.4%)     
  Moderate               102 (29.5%)   24 (38.1%)   78 (27.6%)    
  Low                    96 (27.7%)    30 (47.6%)   66 (23.3%)    
  Unspecified            121 (35.0%)   3 (4.8%)     118 (41.7%)   
  **T stage**                                                     **\<0.001**
  T1--2                  120 (34.7%)   16 (25.4%)   104 (36.7%)   
  T3                     56 (16.2%)    20 (31.7%)   36 (12.7%)    
  T4                     96 (27.7%)    25 (39.7%)   71 (25.1%)    
  Tx                     74 (21.4%)    2 (3.2%)     72 (25.4%)    
  **N stage**                                                     **\<0.001**
  N0                     152 (43.9%)   12 (19.0%)   138 (47.8%)   
  N+                     136 (39.3%)   49 (77.8%)   87 (30.7%)    
  Nx                     58 (16.8%)    2 (3.2%)     56 (19.8%)    
  **Radiotherapy**                                                0.250
  No evidence            308 (89.0%)   53 (84.1%)   255 (90.1%)   
  Yes                    38 (11.0%)    10 (15.9%)   28 (9.9%)     
  **Chemotherapy**                                                0.897
  No evidence            115 (33.2%)   21 (33.3%)   94 (33.2%)    
  Yes                    231 (66.8%)   42 (66.7%)   189 (66.8%)   

**Notes:** *P*\<0.05 is considered statistically significant. Statistically significant values are shown in bold.

**Abbreviations:** PSM, propensity score matching; PTR, primary tumor resection.

###### 

Baseline characteristics of metastatic ampullary cancer patients after PSM

  Characteristics        Total        PTR          No-PTR       *P*-value
  ---------------------- ------------ ------------ ------------ -----------
                                                                
  **Age at diagnosis**                                          0.457
  Mean ± SD              62.3±11.3    61.4±11.7    63.2±10.9    
  **Sex**                                                       0.519
  Female                 36 (40.0%)   20 (44.4%)   16 (35.6%)   
  Male                   54 (60.0%)   25 (55.6%)   29 (64.4%)   
  **Race**                                                      0.524
  White                  60 (66.7%)   30 (66.6%)   30 (66.7%)   
  Black                  19 (21.1%)   8 (17.8%)    11 (24.4%)   
  Other                  11 (12.2%)   7 (15.6%)    4 (8.9%)     
  **Tumor size, cm**                                            0.218
  \<3                    34 (37.8%)   15 (33.3%)   19 (42.2%)   
  ≥3                     36 (40.0%)   22 (48.9%)   14 (31.1%)   
  Unspecified            20 (22.2%)   8 (17.8%)    12 (26.7%)   
  **Grade**                                                     0.119
  High                   12 (13.3%)   4 (8.9%)     8 (17.8%)    
  Moderate               26 (28.9%)   15 (33.3%)   11 (24.4%)   
  Low                    40 (44.4%)   23 (51.1%)   17 (37.8%)   
  Unspecified            12 (13.4%)   3 (6.7%)     9 (20.0%)    
  **T stage**                                                   0.339
  T1--2                  23 (25.5%)   10 (22.2%)   13 (28.9%)   
  T3                     25 (27.8%)   16 (35.6%)   9 (20.0%)    
  T4                     34 (37.8%)   17 (37.8%)   17 (37.8%)   
  Tx                     8 (8.9%)     2 (4.4%)     6 (13.3%)    
  **N stage**                                                   0.180
  N0                     21 (23.3%)   10 (22.2%)   11 (24.4%)   
  N+                     60 (66.7%)   33 (73.3%)   27 (60.0%)   
  Nx                     9 (10.0%)    2 (4.5%)     7 (15.6%)    
  **Radiotherapy**                                              0.771
  No evidence            76 (84.4%)   39 (86.7%)   37 (82.2%)   
  Yes                    14 (15.6%)   6 (13.3%)    8 (17.8%)    
  **Chemotherapy**                                              0.060
  No evidence            25 (27.8%)   17 (37.8%)   8 (17.8%)    
  Yes                    65 (72.2%)   28 (62.2%)   37 (82.2%)   

**Notes:** PSM was performed according to race, tumor size, grade, T stage and N stage with a caliper of 0.005. *P*\<0.05 is considered statistically significant.

**Abbreviations:** PSM, propensity score matching; PTR, primary tumor resection.

###### 

Multivariate Cox regression models of prognostic factors for overall and cancer-specific survival

  Characteristics               Overall survival       Cancer-specific survival                          
  ----------------------------- ---------------------- -------------------------- ---------------------- -------------
                                                                                                         
  **Age at diagnosis**                                                                                   
  For every 1-year increase     1.012 (1.000--1.024)   0.051                      1.010 (0.998--1.022)   0.114
  **Sex**                                                                                                
  Male vs female                0.902 (0.704--1.156)   0.415                      0.952 (0.737--1.229)   0.706
  **Race**                                                                                               
  Black vs white                1.126 (0.795--1.595)   0.505                      1.129 (0.785--1.624)   0.513
  Other vs white                0.980 (0.670--1.434)   0.917                      0.991 (0.669--1.469)   0.966
  **Tumor size, cm**                                                                                     
  ≥3 vs \<3                     0.884 (0.635--1.232)   0.468                      0.854 (0.607--1.201)   0.364
  Unspecified vs \<3            1.076 (0.787--1.469)   0.647                      1.009 (0.732--1.391)   0.956
  **Grade**                                                                                              
  Moderate vs high              1.559 (0.972--2.501)   0.053                      1.555 (0.950--2.543)   0.079
  Low vs high                   1.836 (1.128--2.987)   **0.014**                  1.829 (1.101--3.039)   **0.020**
  Unspecified vs high           1.182 (0.746--1.875)   0.476                      1.183 (0.732--1.913)   0.492
  **T stage**                                                                                            
  T3--4 vs T1--2                0.960 (0.724--1.272)   0.775                      1.011 (0.755--1.353)   0.944
  Tx vs T1--2                   0.921 (0.644--1.318)   0.654                      0.934 (0.642--1.357)   0.719
  **N stage**                                                                                            
  N+ vs N0                      1.205 (0.902--1.609)   0.264                      1.213 (0.898--1.638)   0.208
  Nx vs N0                      1.429 (1.004--2.034)   **0.048**                  1.438 (0.999--2.070)   0.051
  **Radiation**                                                                                          
  Yes vs no evidence            1.442 (0.984--2.115)   0.061                      1.304 (0.866--1.964)   0.204
  **Chemotherapy**                                                                                       
  Yes vs no evidence            0.472 (0.365--0.609)   **\<0.001**                0.465 (0.357--0.606)   **\<0.001**
  **Primary tumor resection**                                                                            
  Yes vs no evidence            0.365 (0.251--0.531)   **\<0.001**                0.331 (0.223--0.492)   **\<0.001**

**Notes:** *P*\<0.05 is considered statistically significant. Statistically significant values are shown in bold.

[^1]: These authors contributed equally to this work
